These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31693811)

  • 1. Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Ceramides.
    Samuel VT; Shulman GI
    N Engl J Med; 2019 Nov; 381(19):1866-1869. PubMed ID: 31693811
    [No Abstract]   [Full Text] [Related]  

  • 2. Ceramides: A Cause of Insulin Resistance in Nonalcoholic Fatty Liver Disease in Both Murine Models and Humans.
    Yki-Järvinen H
    Hepatology; 2020 Apr; 71(4):1499-1501. PubMed ID: 31899812
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
    Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
    J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
    Régnier M; Polizzi A; Guillou H; Loiseau N
    Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study.
    Erkan G; Sayın I; Polat FB; Çorakçı A; Ataç GK; Değertekin H
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():63-8. PubMed ID: 25910371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis.
    Apostolopoulou M; Gordillo R; Koliaki C; Gancheva S; Jelenik T; De Filippo E; Herder C; Markgraf D; Jankowiak F; Esposito I; Schlensak M; Scherer PE; Roden M
    Diabetes Care; 2018 Jun; 41(6):1235-1243. PubMed ID: 29602794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Moh Moh MA; Jung CH; Lee B; Choi D; Kim BY; Kim CH; Kang SK; Mok JO
    Diab Vasc Dis Res; 2019 Mar; 16(2):186-195. PubMed ID: 30428692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical importance of the nonalcoholic fatty liver disease: a review.
    Chumak AA; Ovsyannikova LM; Sarkisova EA; Gasanova EV
    Probl Radiac Med Radiobiol; 2013; (18):277-88. PubMed ID: 25191732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.
    Kurek K; Piotrowska DM; Wiesiołek-Kurek P; Łukaszuk B; Chabowski A; Górski J; Zendzian-Piotrowska M
    Liver Int; 2014 Aug; 34(7):1074-83. PubMed ID: 24106929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considering the Links Between Nonalcoholic Fatty Liver Disease and Insulin Resistance: Revisiting the Role of Protein Kinase C ε.
    Samuel VT; Petersen MC; Gassaway BM; Vatner DF; Rinehart J; Shulman GI
    Hepatology; 2019 Dec; 70(6):2217-2220. PubMed ID: 31220350
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term fatty liver-induced insulin resistance in orotic acid-induced nonalcoholic fatty liver rats.
    Han X; Liu C; Xue Y; Wang J; Xue C; Yanagita T; Gao X; Wang Y
    Biosci Biotechnol Biochem; 2016; 80(4):735-43. PubMed ID: 26775542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on lipid species and paediatric nonalcoholic fatty liver disease.
    Mann JP; Feldstein AE; Nobili V
    Curr Opin Clin Nutr Metab Care; 2017 Mar; 20(2):110-116. PubMed ID: 27906700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance.
    Kwak MS; Kim D; Chung GE; Kim W; Kim YJ; Yoon JH
    Liver Int; 2015 Mar; 35(3):944-52. PubMed ID: 24684289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Mean Platelet Volume Actually Significantly Higher in Patients With Nonalcoholic Fatty Liver Disease?
    Beyan C; Beyan E
    J Clin Gastroenterol; 2015; 49(10):888. PubMed ID: 26302499
    [No Abstract]   [Full Text] [Related]  

  • 16. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research progress on therapeutic targets of active components in Chinese herbs for treatment of nonalcoholic fatty liver disease].
    Pan YT; Xu FY; Yu XZ; Shang WB
    Zhongguo Zhong Yao Za Zhi; 2017 Mar; 42(6):1109-1112. PubMed ID: 29027424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Errors in meta-analysis on prevalence of nonalcoholic fatty liver disease.
    Roerecke M; Rehm J; Neuman M
    Hepatology; 2016 Oct; 64(4):1389-90. PubMed ID: 27038346
    [No Abstract]   [Full Text] [Related]  

  • 19. The effects of Zataria multiflora Boiss. (Shirazi thyme) on nonalcoholic fatty liver disease and insulin resistance: A randomized double-blind placebo-controlled clinical trial.
    Zamani N; Shams M; Nimrouzi M; Zarshenas MM; Abolhasani Foroughi A; Fallahzadeh Abarghooei E; Fattahi MR
    Complement Ther Med; 2018 Dec; 41():118-123. PubMed ID: 30477827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
    Polyzos SA; Goulis DG; Kountouras J
    Ann Hepatol; 2015; 14(6):941-3. PubMed ID: 26436371
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.